Cargando…

Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers

Immunotherapy may provide valid alternative therapy for patients with hormone-refractory metastatic prostate cancer. However, if the tumor environment exerts a suppressive action on antigen-specific tumor-infiltrating lymphocytes (TIL), immunotherapy will achieve little, if any, success. In this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bronte, Vincenzo, Kasic, Tihana, Gri, Giorgia, Gallana, Keti, Borsellino, Giovanna, Marigo, Ilaria, Battistini, Luca, Iafrate, Massimo, Prayer-Galetti, Tommaso, Pagano, Francesco, Viola, Antonella
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213151/
https://www.ncbi.nlm.nih.gov/pubmed/15824085
http://dx.doi.org/10.1084/jem.20042028
_version_ 1782148836059250688
author Bronte, Vincenzo
Kasic, Tihana
Gri, Giorgia
Gallana, Keti
Borsellino, Giovanna
Marigo, Ilaria
Battistini, Luca
Iafrate, Massimo
Prayer-Galetti, Tommaso
Pagano, Francesco
Viola, Antonella
author_facet Bronte, Vincenzo
Kasic, Tihana
Gri, Giorgia
Gallana, Keti
Borsellino, Giovanna
Marigo, Ilaria
Battistini, Luca
Iafrate, Massimo
Prayer-Galetti, Tommaso
Pagano, Francesco
Viola, Antonella
author_sort Bronte, Vincenzo
collection PubMed
description Immunotherapy may provide valid alternative therapy for patients with hormone-refractory metastatic prostate cancer. However, if the tumor environment exerts a suppressive action on antigen-specific tumor-infiltrating lymphocytes (TIL), immunotherapy will achieve little, if any, success. In this study, we analyzed the modulation of TIL responses by the tumor environment using collagen gel matrix–supported organ cultures of human prostate carcinomas. Our results indicate that human prostatic adenocarcinomas are infiltrated by terminally differentiated cytotoxic T lymphocytes that are, however, in an unresponsive status. We demonstrate the presence of high levels of nitrotyrosines in prostatic TIL, suggesting a local production of peroxynitrites. By inhibiting the activity of arginase and nitric oxide synthase, key enzymes of L-arginine metabolism that are highly expressed in malignant but not in normal prostates, reduced tyrosine nitration and restoration of TIL responsiveness to tumor were achieved. The metabolic control exerted by the tumor on TIL function was confirmed in a transgenic mouse prostate model, which exhibits similarities with human prostate cancer. These results identify a novel and dominant mechanism by which cancers induce immunosuppression in situ and suggest novel strategies for tumor immunotherapy.
format Text
id pubmed-2213151
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-22131512008-03-11 Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers Bronte, Vincenzo Kasic, Tihana Gri, Giorgia Gallana, Keti Borsellino, Giovanna Marigo, Ilaria Battistini, Luca Iafrate, Massimo Prayer-Galetti, Tommaso Pagano, Francesco Viola, Antonella J Exp Med Article Immunotherapy may provide valid alternative therapy for patients with hormone-refractory metastatic prostate cancer. However, if the tumor environment exerts a suppressive action on antigen-specific tumor-infiltrating lymphocytes (TIL), immunotherapy will achieve little, if any, success. In this study, we analyzed the modulation of TIL responses by the tumor environment using collagen gel matrix–supported organ cultures of human prostate carcinomas. Our results indicate that human prostatic adenocarcinomas are infiltrated by terminally differentiated cytotoxic T lymphocytes that are, however, in an unresponsive status. We demonstrate the presence of high levels of nitrotyrosines in prostatic TIL, suggesting a local production of peroxynitrites. By inhibiting the activity of arginase and nitric oxide synthase, key enzymes of L-arginine metabolism that are highly expressed in malignant but not in normal prostates, reduced tyrosine nitration and restoration of TIL responsiveness to tumor were achieved. The metabolic control exerted by the tumor on TIL function was confirmed in a transgenic mouse prostate model, which exhibits similarities with human prostate cancer. These results identify a novel and dominant mechanism by which cancers induce immunosuppression in situ and suggest novel strategies for tumor immunotherapy. The Rockefeller University Press 2005-04-18 /pmc/articles/PMC2213151/ /pubmed/15824085 http://dx.doi.org/10.1084/jem.20042028 Text en Copyright © 2005, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Article
Bronte, Vincenzo
Kasic, Tihana
Gri, Giorgia
Gallana, Keti
Borsellino, Giovanna
Marigo, Ilaria
Battistini, Luca
Iafrate, Massimo
Prayer-Galetti, Tommaso
Pagano, Francesco
Viola, Antonella
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers
title Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers
title_full Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers
title_fullStr Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers
title_full_unstemmed Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers
title_short Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers
title_sort boosting antitumor responses of t lymphocytes infiltrating human prostate cancers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213151/
https://www.ncbi.nlm.nih.gov/pubmed/15824085
http://dx.doi.org/10.1084/jem.20042028
work_keys_str_mv AT brontevincenzo boostingantitumorresponsesoftlymphocytesinfiltratinghumanprostatecancers
AT kasictihana boostingantitumorresponsesoftlymphocytesinfiltratinghumanprostatecancers
AT grigiorgia boostingantitumorresponsesoftlymphocytesinfiltratinghumanprostatecancers
AT gallanaketi boostingantitumorresponsesoftlymphocytesinfiltratinghumanprostatecancers
AT borsellinogiovanna boostingantitumorresponsesoftlymphocytesinfiltratinghumanprostatecancers
AT marigoilaria boostingantitumorresponsesoftlymphocytesinfiltratinghumanprostatecancers
AT battistiniluca boostingantitumorresponsesoftlymphocytesinfiltratinghumanprostatecancers
AT iafratemassimo boostingantitumorresponsesoftlymphocytesinfiltratinghumanprostatecancers
AT prayergalettitommaso boostingantitumorresponsesoftlymphocytesinfiltratinghumanprostatecancers
AT paganofrancesco boostingantitumorresponsesoftlymphocytesinfiltratinghumanprostatecancers
AT violaantonella boostingantitumorresponsesoftlymphocytesinfiltratinghumanprostatecancers